Quality of care in people requiring hospital admission for gout in Aotearoa New Zealand: a nationwide analysis

• Published in: Internal medicine journal 2022-12, Vol.52 (12), p.2136-2142
• Main Authors: Murdoch, Rachel, Jones, Peter, Greenwell, James, Dalbeth, Nicola
• Format: Article
• Language: English
• Subjects: Aftercare; Allopurinol; Allopurinol - therapeutic use; Diagnosis; Female; Gout; Gout - diagnosis; Gout - drug therapy; Gout - epidemiology; Gout Suppressants - therapeutic use; hospitalisation; Hospitals; Humans; New Zealand - epidemiology; Patient Discharge; quality of care; Quality of Health Care; urate
• ISSN: 1444-0903; 1445-5994
• DOI: 10.1111/imj.15470

Background The quality of care for patients admitted with a primary diagnosis of gout, both before and after admission, has not been systematically examined. Aims To understand national trends in hospital admission for a primary diagnosis of gout in Aotearoa New Zealand over the past 10 years and the quality of care for gout received by these patients before and after the admission. Methods Data from the Aotearoa New Zealand National Collections from 1 January 2007 to 31 December 2019 were analysed to determine rates of hospital admission for a primary diagnosis of gout. Admission data include cost−weight analysis, as well as quality of care data including gout‐specific medication dispensing in the year prior and year after admission. Results There were 13 721 admissions with a primary diagnosis of gout over the analysis period, with an average cost per admission in 2019 of NZ$4301. The rate of admission per 100 000 population was highest in Pacific peoples followed by Māori. Although dispensing of any allopurinol increased in the year after admission, rates of regular allopurinol dispensing remained low; 38.1% for admissions in 2018. Patients who were younger (especially 20–44 years), not enrolled in a primary health organisation before admission and female had lower rate of regular allopurinol after admission. Conclusion In this nationwide study, rates of admission for gout were highest in Pacific peoples and in Māori. Rates of regular allopurinol dispensing were low even after admission for a primary diagnosis of gout. These findings highlight the need for improvements in gout management in Aotearoa New Zealand, including in post‐discharge planning from secondary care inpatient services.